Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,155 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Oral semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 61
States / cities: Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more

Conditions: End Stage Kidney Disease
Interventions: CSL300, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 166
States / cities: Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more

Conditions: Brain Activity
Interventions: Methylene Blue (USP grade, 280mg oral), Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 70
States / cities: Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more

Conditions: Leukemia
Interventions: filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 51
States / cities: Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more

Conditions: Advanced Solid Tumors
Interventions: BAY2965501, Pembrolizumab, Platinum-based Chemotherapy; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 843
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 550 more

Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Interventions: Stroke/Thrombectomy/Aneurysm-specific surgical procedures; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Year to 120 Years
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2055
U.S. locations: 54
States / cities: Birmingham, Alabama • Loma Linda, California • Santa Barbara, California + 48 more

Conditions: Urinary Bladder Neoplasms
Interventions: Nivolumab, BCG, BMS-986205; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 25
States / cities: Los Angeles, California • Riverside, California • San Francisco, California + 21 more

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: VisionQuest Biomedical LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Albuquerque, New Mexico • San Antonio, Texas

Conditions: Osteoarthritis
Interventions: tanezumab, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 97
States / cities: Jonesboro, Arkansas • Aurora, Colorado • Centennial, Colorado + 42 more

Conditions: Hemophilia A
Interventions: Nuwiq; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: Satraplatin plus radiation therapy; Drug
Lead sponsor: Agennix; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Francisco, California • Dallas, Texas • San Antonio, Texas + 1 more

Conditions: Primary Mediastinal Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 215
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more

Conditions: Brain and Central Nervous System Tumors
Interventions: suramin, radiation therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Adverse Events
Interventions: Irrisept, Standard of Care; Device
Lead sponsor: Irrimax Corporation; Industry
Eligibility: Not listed
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Cancer-related Problem/Condition, Head and Neck Cancer, Pain
Interventions: glutamine, radiation therapy, l-glutamine placebo; Dietary Supplement · Radiation · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 106
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Escondido, California • La Jolla, California • San Mateo, California + 16 more

Conditions: Peripheral Arterial Disease, Lower Extremity Arterial Disease
Interventions: EverFlex™ Self-Expanding Peripheral Stent System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Modesto, California • Sacramento, California + 20 more

Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more

Conditions: Breast Cancer
Interventions: bevacizumab, capecitabine, cyclophosphamide, docetaxel, doxorubicin hydrochloride (Adriamycin), gemcitabine hydrochloride; Biological · Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 1,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 432
States / cities: Little Rock, Arkansas • Castro Valley, California • Fremont, California + 287 more

Conditions: Defect of Articular Cartilage, Knee Injuries
Interventions: Particulated Juvenile Articular Cartilage; Other
Lead sponsor: Zimmer Orthobiologics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 16
States / cities: Los Angeles, California • San Deigo, California • Aurora, Colorado + 13 more

Conditions: Gliosarcoma, Recurrent Glioblastoma
Interventions: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Castro Valley, California + 43 more

Search by objective public record fields.

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Stroke Thrombectomy and Aneurysm Registry

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Computer-based Screening for Diabetic Retinopathy

Tanezumab and Nerve Function In Arthritis Patients

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Retrospective Independent Safety Review of Closed Irrisept Study

S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

EverFlex Post Approval Study

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

DeNovo NT Natural Tissue Graft Stratified Knee Study

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma